ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag disease medicine policy art

Artist’s rendition of light blue monkeypox viruses in front of a black background.
FDA To Stretch Monkeypox Vaccine Supply via Intradermal Injection
Shafaq Zia | Aug 12, 2022 | 4 min read
The newly authorized intradermal vaccination only requires one-fifth of the usual vaccine dose. This will help stretch out the limited vaccine supply, experts say, but only if healthcare personnel receive sufficient training.
Turning Points: Making Policy, A Career
Karen Young Kreeger | Jun 9, 2002 | 2 min read
Passion leads many scientists away from the bench and into world policy organizations. But policy making and diplomacy require both art and science, and universities and fellowship programs can help life scientists acquire skills they don't always learn in their labs. Take Achal Bhatt, an analyst in the National Immunization Program (NIP) at the Centers for Disease Control and Prevention (CDC) in Atlanta. As Bhatt worked toward her PhD on mycobacteria, which cause tuberculosis, she became incre
Concerns over Efficacy and Cost of Muscle Wasting Treatments
Ruth Williams | Nov 11, 2020 | 5 min read
Two new medications for treating a rare and deadly neuromuscular disease have high prices and questionable efficacies, say scientists.
Supplement: Art Caplan
Karen Pallarito | Jan 1, 2008 | 4 min read
Art Caplan By Karen Pallarito A conversation with Penn's renowned ethicist. RELATED ARTICLES Innovative Technology Daniel Skovronsky: Scientist and leader Turning Tobacco into Therapies Biofuel: The Potential Magic Bullet Britton Chance: Still searching for answers Technology Roundup DUSTIN FENSTERMACHER / WONDERFUL MACHINE As a Columbia University philosophy student in the 1970s, Arthur Caplan listened to ongoing discussions about the ethics of
Capsule Reviews
Bob Grant | Nov 1, 2013 | 4 min read
Tracks and Shadows, The Gap, The Cure in the Code, and An Appetite for Wonder
Institute of Medicine Members
Edward Silverman | Nov 24, 1996 | 6 min read
Clay M. Armstrong professor of physiology, University of Pennsylvania School of Medicine, Philadelphia John P. Atkinson head, John Milliken Department of Internal Medicine, Washington University School of Medicine, St. Louis Marion J. Ball chief information officer, Information Services, University of Maryland, Baltimore Alfred O. Berg professor and associate chairman, department of family medicine, University of Washington, Seattle Merton Bernfield Clement A. Smith Professor of Pediatri
Decisions, Decisions: NIH's Disease-By-Disease Allocations Draw New Fire
Bruce Agnew | Mar 29, 1998 | 8 min read
'BODY-COUNT BUDGETING'? Rep. Ernest Istook (R-Okla.) is concerned that diseases that cost taxpayers the most money may not be getting a proportionate amount of NIH funds. For the third year in a row, the National Institutes of Health came under fire this month for slighting some diseases and favoring more politically correct ills when it parcels out its research-funding billions. "What this whole thing boils down to," NIH director Harold Varmus recently told a special Institute of Medicine (I
FDA Approves Gene Therapy for Spinal Muscular Atrophy
Ashley Yeager | May 27, 2019 | 3 min read
At $2 million for a single dose, Novartis’s Zolgensma is the most expensive medicine to date, but still less expensive over a lifetime than another approved drug for the rare genetic disease.
Progress In Medicine Unites Recipients Of 1997 Lasker Awards
Stephen Hoffert | Oct 26, 1997 | 8 min read
The Albert and Mary Lasker Foundation honored three medical researchers at an awards luncheon on September 26 in New York. According to a foundation official, the 1997 award winners represent the distinct approaches and scientific perspectives that must combine in the fight against disease. Victor A. McKusick, a professor of genetics at Johns Hopkins University, was given the Special Achievement in Medical Science Award; Mark S. Ptashne, the Ludwig Professor of Molecular Biology at the Mem
Stung by the Pope and Health Studies, Congress Mulls a Policy Change for Cuba
Steve Bunk | May 24, 1998 | 10 min read
Long-standing public and political contention over the effects of the United States' economic embargo on the health of the Cuban people appears to be approaching a watershed. The proponents of a change in U.S. policy base their arguments on the results of scientific research over recent years that indicate the embargo has contributed to unhealthy shortages of food and medicine in Cuba. In both houses of Congress, bills are being considered that would exempt from the embargo the sale of food to

Run a Search

ADVERTISEMENT